Trials / Completed
CompletedNCT00836667
Sertraline Hydrochloride 100 mg Tablets, Fed
Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fed Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Teva Pharmaceuticals USA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to compare the rate and extent of absorption of sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference) administered as 1 x 100 mg tablet under fed conditions.
Detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoloft® 100 mg Tablets | 1 x 100 mg, single-dose fed |
| DRUG | Sertraline hydrochloride 100 mg Tablets | 1 x 100 mg, single-dose fed |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2002-04-01
- Completion
- 2002-04-01
- First posted
- 2009-02-04
- Last updated
- 2024-08-19
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00836667. Inclusion in this directory is not an endorsement.